西达本胺在造血干细胞移植预处理方案中的研究进展  

Research progress of chidamide in the conditioning regimen of hematopoietic stem cell transplantation

作　　者：王蕾(综述)[1] 付玥玥(综述) 李丽敏(审校)[1] 周晋(审校)[1] WANG Lei;FU Yueyue;LI Limin;ZHOU Jin(Department of Hematology,First Affiliated Hospital of Harbin Medical University,Harbin 150000,China)

机构地区：[1]哈尔滨医科大学附属第一医院血液内科,哈尔滨150000

出　　处：《临床与病理杂志》2022年第3期762-766,共5页Journal of Clinical and Pathological Research

摘　　要：造血干细胞移植(hematopoietic stem cell transplantation,HSCT)是临床治疗恶性血液病的有效方式之一。预处理药物的选择与HSCT的成功及预后紧密相关。西达本胺属于组蛋白去乙酰化物酶抑制剂(histone deacetylase inhibitors,HDACi),可以靶向阻断HDAC的去乙酰化作用,具有高效低毒的特点,已成为重要的新型抗肿瘤药物,近年来在临床上经常作为预处理药物用于HSCT,并已取得较好的效果。Hematopoietic stem cell transplantation(HSCT) is one of the effective ways to treat malignant hematological diseases. The selection of pretransplant conditioning drugs is closely related to the success and prognosis of hematopoietic stem cell transplantation. Chidamide is a histone deacetylase inhibitor(HDACi) that can target and block the deacetylation of HDAC. With the characteristics of high effciency and low toxicity, it has become an important new anti-tumor drug. In recent years, it has often been used as a drug that incorporated into pretransplant conditioning regimens for hematopoietic stem cell transplantation and has achieved good results.

关 键 词：西达本胺 预处理方案 造血干细胞移植 

分 类 号：R73[医药卫生—肿瘤]